Trial Profile
A global, phase I, pharmacokinetic study investigating bevacizumab biosimilar [MYL-1402O]
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- 09 Dec 2015 New trial record